DTIL — Precision Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $60.66m
- -$3.33m
- $68.70m
- 31
- 69
- 24
- 36
Annual cashflow statement for Precision Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -109 | -30.6 | -112 | -61.3 | 7.17 |
| Depreciation | |||||
| Non-Cash Items | 14.9 | -8.82 | 34 | 11.9 | -15 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.01 | 19.6 | 24.1 | -41.5 | -54 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -87.4 | -10.9 | -45.8 | -84.1 | -58.4 |
| Capital Expenditures | -5.03 | -5.8 | -3.32 | -2.28 | -0.275 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | 8.11 | 0.06 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -5.03 | -5.8 | -3.32 | 5.83 | -0.215 |
| Financing Cash Flow Items | 0.64 | 0.791 | 0.443 | 0.37 | 0.249 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.33 | 70.5 | 95 | 5.39 | 50.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -91.1 | 53.9 | 45.9 | -72.9 | -8.21 |